.jpg)
In an effort to make precision medicine more accessible, Rennova Health Inc. subsidiary Advanced Molecular Services Group (AMS Group) has partnered with Certainty Health to develop smartphone tools that will help incorporate patients’ genetic backgrounds into psychiatric treatment.
"Precision medicine is great science, but still too expensive for the average family,” AMS Group CEO Scott Jenkins said in a release. “Patients and their families need access to advances in diagnostic technologies and interpretation. Rennova's AMS Group is bringing its patented pharmacogenomic platform directly to consumers."
Using the Certainty Health brand, Rennova will market consumer-facing genetic tests, developed by the AMS Group, through a mobile platform. The tests will help patients and their physicians better determine what drugs and what doses will best treat their psychiatric disorders.
"We look forward to working with Rennova Health to expand a mobile precision medicine platform to immediately address the unmet needs of patients and their caregivers for relevant molecular information impacting psychiatry today," Certainty Health President Chris Yoo said in the release. "Rennova's incredibly rich and growing databases of pharmacogenomic drug metabolism data represents over a decade of real-world diagnostic results for multiple diseases and together with Rennova, we will democratize access to this knowledge for the benefit of patients."
